
AIM ImmunoTech Inc.
94
Recent developments highlight AIM ImmunoTech's clinical progress with Ampligen, patent achievements, capital raises, and regulatory compliance.
- AIM ImmunoTech highlighted the opportunity for Ampligen and outlined key milestones for 2027, emphasizing ongoing clinical development and patent protections [N1].
- The company advanced Ampligen in its Phase 2 pancreatic cancer study, dosing the last patient early in the DURIPANC trial [N2][N4].
- AIM reported a net loss for Q2 2026 and indicated topline Phase 2 pancreatic cancer data is due in Q1 2027 [N3].
- The company regained NYSE American compliance by increasing stockholders' equity above the $6 million minimum as of June 2026 [N7].
- AIM completed multiple equity transactions during 2026, including a $2.4 million direct offering and private placement of warrants [N8].
- The Phase 2 DURIPANC study enrollment was completed, supporting ongoing clinical evaluation of Ampligen in pancreatic cancer [N6].
- The company secured broad patent protections for Ampligen in the US, Europe, UK, and Japan, including combination therapies with Keytruda and treatment for long COVID [N1].
- Liquidity remains supported by cash and equivalents of approximately $6.9 million as of September 30, 2026, with a current ratio of 2.75 [S2].
AIM ImmunoTech Inc. operates as a clinical-stage biotechnology company developing immunotherapy products, primarily Ampligen. Ampligen is under clinical evaluation for treatment of pancreatic cancer and long COVID, among other indications. The company has advanced its Phase 2 DURIPANC study in pancreatic cancer, completing patient dosing early and anticipating topline data in early 2027. AIM has secured patent protections in the US, Europe, UK, and Japan for Ampligen, including combination therapies with Keytruda. Financially, AIM has raised capital through rights offerings and direct offerings in 2026, improving liquidity and regaining NYSE American compliance by maintaining stockholders' equity above $6 million. The company reported a net loss for the nine months ended September 30, 2026, with cash and equivalents sufficient to cover current liabilities. The business model centers on clinical development and intellectual property management in the biotechnology sector.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. AIM ImmunoTech Inc. is a clinical-stage biotechnology company focused on developing its immunotherapy product Ampligen for multiple indications including pancreatic cancer and long COVID. The company has ongoing Phase 2 clinical trials, with topline data for pancreatic cancer expected in Q1 2027. As of September 30, 2026, AIM reported a net loss of $3.143 million and held $6.887 million in cash and equivalents, maintaining a current ratio of 2.75. The company completed multiple equity raises in 2026, increasing stockholders' equity above the NYSE American minimum listing requirement. Patent protections have been secured in key markets for Ampligen. Risks include ongoing net losses, potential dilution from outstanding warrants and convertible preferred stock, and the need to maintain NYSE listing compliance.
The company has advanced its Phase 2 clinical trial for Ampligen in pancreatic cancer, completing patient dosing early and preparing for topline data release. Patent protections in multiple jurisdictions for Ampligen and its combination therapies provide intellectual property strength. Recent capital raises have improved liquidity and restored NYSE American compliance, supporting ongoing development activities. The management team's extensive experience in biotech and regulatory affairs supports execution capabilities.
AIM ImmunoTech continues to incur net losses and depends on capital raises, which have resulted in significant dilution risk due to outstanding warrants and convertible preferred stock. The company must maintain stockholders' equity above NYSE American minimums to avoid delisting, which poses a risk to liquidity and market access. Clinical trial outcomes remain uncertain, and failure to achieve positive results or regulatory approvals could materially impact the business. The absence of commercial products limits revenue generation and increases reliance on external financing.
AIM ImmunoTech's moat derives from its proprietary immunotherapy product Ampligen, supported by multiple patents granted in major markets including the US, Europe, UK, and Japan. The company's focus on niche indications such as pancreatic cancer and long COVID, combined with ongoing clinical trials and regulatory progress, creates barriers to entry. The specialized expertise of its management and board in biotechnology, legal, and regulatory domains further supports its competitive positioning. However, as a clinical-stage company without commercial products, its moat is contingent on successful clinical development and regulatory approvals.
• Dilution Risk: Outstanding warrants to purchase approximately 47.4 million shares and convertible preferred stock convertible into common shares pose significant dilution risk to existing stockholders if exercised or converted.
• NYSE American Listing Compliance: The company must maintain stockholders' equity of at least $6 million and a minimum share price to avoid suspension or delisting, which could impair liquidity and capital raising ability.
• Clinical Development Risk: Ampligen is in clinical-stage development with ongoing Phase 2 trials; failure to achieve positive clinical outcomes or regulatory approvals could adversely affect the company's prospects.
• Financial Losses and Capital Dependence: The company has reported net losses and depends on equity financing to fund operations, which may not be sustainable long-term without successful product commercialization.
Business trends: Continued clinical development of Ampligen in pancreatic cancer and other indications, supported by expanding patent protections and capital raises.
Execution milestones: Completion of Phase 2 DURIPANC enrollment and dosing, upcoming topline data release, and maintenance of NYSE American listing compliance.
Key risks: Clinical trial outcome uncertainties, dilution from outstanding warrants and convertible preferred stock, and ongoing need to maintain regulatory and listing standards.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- AIM ImmunoTech Inc. is a clinical-stage biotechnology company focused on developing immunotherapy products, notably Ampligen.
- Ampligen is being developed for multiple indications including pancreatic cancer and long COVID, with ongoing Phase 2 clinical trials.
- The company completed a rights offering in March 2026 raising approximately $1.8 million gross proceeds.
- AIM ImmunoTech maintains listing on the NYSE American and must maintain stockholders' equity of at least $6 million to avoid delisting.
- As of September 30, 2026, the company had cash and cash equivalents of $6.887 million and current assets of $7.336 million against current liabilities of $2.672 million, resulting in a current ratio of 2.75 and a cash ratio of 3.01.
- The company reported a net loss of $3.143 million for the nine months ended September 30, 2026, with basic and diluted EPS of -$0.21 per share.
- AIM ImmunoTech has secured patent protections in Europe, the UK, Japan, and the US for Ampligen, including patents for combination therapies with Keytruda and for treatment of long COVID.
- The company completed enrollment and dosed the last patient early in the Phase 2 DURIPANC study for Ampligen in pancreatic cancer.
- Topline Phase 2 pancreatic cancer data from the DURIPANC study is due in Q1 2027.
- The company raised approximately $10.4 million gross proceeds during the nine months ended September 30, 2026, through multiple equity transactions including rights offerings and registered direct offerings.
- Outstanding warrants to purchase approximately 47.4 million shares and convertible preferred stock could cause significant dilution if exercised or converted.
- The company regained NYSE compliance with increased stockholders' equity as of June 2026.
- Management and board members have extensive experience in biotechnology, legal, regulatory, and financial fields relevant to the company's operations.
Generated 2026-11-15
- S1 | 2026-03-27 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-06 | www.nasdaq.com | AIM ImmunoTech Inc. Highlights Ampligen Opportunity and 2027 Milestones | https://www.nasdaq.com/articles/aim-immunotech-inc-highlights-ampligen-opportunity-and-2027-milestones
- N2 | 2026-09-09 | www.nasdaq.com | AIM ImmunoTech Advances Ampligen In Phase 2 Pancreatic Cancer Study | https://www.nasdaq.com/articles/aim-immunotech-advances-ampligen-phase-2-pancreatic-cancer-study
- N3 | 2026-08-10 | www.nasdaq.com | AIM ImmunoTech Reports Q2 Loss, Topline Phase 2 Pancreatic Cancer Data Due In Q1 2027 | https://www.nasdaq.com/articles/aim-immunotech-reports-q2-loss-topline-phase-2-pancreatic-cancer-data-due-q1-2027
- N4 | 2026-08-04 | www.nasdaq.com | AIM Doses Last Patient Early In Phase 2 DURIPANC For Ampligen In Treating Pancreatic Cancer | https://www.nasdaq.com/articles/aim-doses-last-patient-early-phase-2-duripanc-ampligen-treating-pancreatic-cancer
- N5 | 2026-07-24 | www.nasdaq.com | Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical | https://www.nasdaq.com/articles/zackscom-featured-highlights-include-aim-immunotech-hasbro-fox-cencora-and-intuitive
- N6 | 2026-06-22 | www.nasdaq.com | AIM Advances Phase 2 DURIPANC Study In Pancreatic Cancer; Expects Topline Data In Q1,2027 | https://www.nasdaq.com/articles/aim-advances-phase-2-duripanc-study-pancreatic-cancer-expects-topline-data-q12027
- N7 | 2026-06-16 | www.nasdaq.com | AIM ImmunoTech Regains NYSE Compliance With Increased Stockholders' Equity | https://www.nasdaq.com/articles/aim-immunotech-regains-nyse-compliance-increased-stockholders-equity
- N8 | 2026-05-21 | www.nasdaq.com | AIM ImmunoTech Unveils $2.4 Mln Direct Offering And Private Placement Of Warrants | https://www.nasdaq.com/articles/aim-immunotech-unveils-24-mln-direct-offering-and-private-placement-warrants
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


